NxStage Introduces Web-Based Dosing Calculator
Automated online tool helps physicians to prescribe hemodialysis treatment plans designed to fit patients’ lifestyles
LAWRENCE, Mass., Sept. 23, 2013 /PRNewswire/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the immediate availability of the NxStage Dosing Calculator. Designed for use with the NxStage® System One™, this online tool helps physicians develop prescriptions tailored to patients’ clinical and lifestyle objectives.
Home hemodialysis, particularly when delivered more frequently, is shown to significantly improve patients’ quality-of-life and other important clinical outcomes. Because traditional in-center dialysis treatment schedules are constrained by staffing and time-slot availability, home therapy presents additional flexibility with which to address clinical and lifestyle needs. This readily accessible tool will help clinicians decide upon the course of care to achieve their objectives.
Using formulas from peer-reviewed publications, the Dosing Calculator quickly displays a wide range of therapy frequencies and durations to assist nephrologists in prescribing for a desired dose. This online tool is expected to significantly reduce nephrologist time in calculating and assessing hundreds of possible prescription options to achieve clinical goals.
“We are committed to increasing access to home hemodialysis therapy based upon its life-changing benefits to patients and their families, and ensuring a simple prescription process is important to this goal,” said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. “With this web-based tool, physicians now have a new way to target their clinical goals while giving patients maximum flexibility to live their lives as they wish.”
The interactive online tool is available on the NxStage web site or can be accessed directly at http://dosingcalculator.nxstage.com. The Dosing Calculator is a free service for health care providers.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients’ homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at www.nxstage.com.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations